Top line data to be presented at 2019 Scientific Sessions of American Heart Association Webcast to be held on Monday 18 November at 11.00 ET Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has…
Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders that is part of Alta Life Sciences portfolio, has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In June 2019 Sanifit announced the completion of a €72.2 million (USD 80.9 million) private fundraising to further accelerate the clinical development…
Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis Round led by Spanish investor Caixa Capital Risc Columbus Venture Partners joins Alta Life Sciences as new investors, in addition to international consortium of existing shareholders Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the…
The round led by Alta Life Sciences, will reinforce the most advanced and accurate symptom checker, the only clinically validated in the world Start-up investors such as European-focused Castel Capital, French-based Naos, as well as other “business angels”, have also joined the round Barcelona, 12th of September 2018. Mediktor announces the closure of a Series A funding round for an amount of 3 million euros. Alta Life Sciences Spain I…
Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of Bionure’s lead compound BN201, that has demonstrated its potential to promote neuroprotection and remyelination in the preclinical phase, offering a game-changing solution for neurodegenerative diseases. Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis…
Peptomyc S.L., a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients, announces the closure of a Series A financing of 4.2 million euros. The investment round was led by Alta Life Sciences Spain I FCR, and includes current investors HealthEquity and business angels, that had already participated in the seed round of 2016. RCD, a leading legal firm in the biotech sector, has advised on…
